Description: <b>HCA</b> is a naturally occurring compound primarily known for its potential effects on appetite and lipid metabolism via inhibition of ATP citrate lyase. 1,2-dihydroxy-1,2,3-propanetricarboxylic acid, structurally a hydroxy derivative of citric acid<br>
Derivative of citric acid that is found in a variety of tropical plants including Garcinia cambogia and Hibiscus sabdariffa<br>
Hydroxycitric acid (HCA) is best known for inhibiting ATP citrate lyase (ACLY), a key enzyme that generates cytosolic acetyl-CoA from citrate for lipid and cholesterol synthesis. By reducing ACLY activity and downstream lipogenesis, HCA shifts cellular metabolism and can activate energy-sensing pathways (such as AMPK) in some models. Evidence for direct anticancer cytotoxicity is modest and often linked to metabolic stress rather than primary cytotoxic mechanisms. Oral exposure is influenced by rapid metabolism and conjugation, with systemic bioavailability often limited compared to levels used in many in vitro studies.<br>
<br>
• Hydroxy-Citric Acid (HCA) is a compound extracted from Garcinia cambogia, primarily recognized for its potential effects on lipid metabolism and appetite suppression.<br>
• It has been proposed to inhibit the enzyme ATP citrate lyase, which is involved in converting citrate into acetyl-CoA—a key step in fatty acid synthesis.<br>
• By modulating lipid synthesis pathways, HCA has been studied in the context of obesity and metabolic disorders, with some exploratory research considering its implications in cancer metabolism.<br>
<br>
• Inhibition of ATP Citrate Lyase (ACLY)******<br>
ACLY converts citrate into acetyl-CoA, a building block for fatty acid and cholesterol synthesis. Many cancer cells upregulate lipid synthesis to support membrane production and energy storage; hence, inhibiting ACLY presents a potential strategy to disrupt cancer cell metabolism.<br>
<br>
• Impact on Lipogenesis<br>
Reduced acetyl-CoA production can impair de novo lipogenesis, potentially limiting the proliferation of rapidly dividing cells that have high lipid demands.<br>
<br>
• Interactions with Other Metabolic Pathways (modulation of citrate levels may affect the TCA cycle)<br>
<br>
-Dosages used in weight loss studies typically ranging from 500 mg to 1500 mg per day<br>
Human cyclists: 3.1 mL/kg body wt of an HCA solution (19 g/L) --> 248mg<br>
"Studies have shown that humans can safely ingest 13.5 g of hydroxycitrate per day with plasma levels of 82 mg/L (0.39 mM) achieved". Appetite suppression and weight loss effects are mixed.<br>
Typically, HCA used in dietary weight loss supplement is bound to calcium, which results in a poorly soluble (<50%) and less bioavailable form. Conversely, the structural characteristics of a novel Ca2+/K+ bound (-)-HCA salt (HCA-SX or Super CitriMax) make it completely water soluble as well as bioavailable.<br>
<br>
-HydroxyCitrate (HCA) typically used in a dose of about 1.5g/day(experimental) or more for cancer (inhibition of the Melavonate Pathway?)<br>
<br>
<p><b>Hydroxycitric Acid</b> — Hydroxycitric acid (HCA), particularly the naturally occurring (−)-hydroxycitric acid stereoisomer, is a plant-derived hydroxytricarboxylic acid structurally related to citric acid and best known as a competitive inhibitor of ATP citrate lyase (ACLY). It is classified as a natural small-molecule metabolic modulator and nutraceutical ingredient. The standard abbreviation is HCA. Major botanical sources include the fruit rind of <i>Garcinia gummi-gutta</i> (syn. <i>Garcinia cambogia</i>) and related <i>Garcinia</i> species; commercial preparations commonly supply calcium, potassium, or calcium/potassium hydroxycitrate salts. By limiting ACLY-dependent production of cytosolic acetyl-CoA, HCA can reduce de novo fatty-acid and cholesterol synthesis. Its anticancer evidence is predominantly preclinical and metabolic rather than evidence of clinically established tumor-selective cytotoxicity.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Competitive inhibition of ATP citrate lyase (ACLY), reducing conversion of citrate to cytosolic acetyl-CoA and oxaloacetate.</li>
<li>Suppression of de novo lipogenesis and cholesterol synthesis downstream of reduced acetyl-CoA availability.</li>
<li>Metabolic stress with AMPK activation in susceptible cancer models; in chronic myelogenous leukemia, HCA produced an unusual concurrent increase in AMPK and mTOR signaling.</li>
<li>Induction of endoplasmic-reticulum stress and the eIF2α/ATF4 unfolded-protein-response pathway, contributing to G2/M cell-cycle arrest and DNA fragmentation in CML models.</li>
<li>Promotion of apoptosis in selected tumor models, including ↑ BAX and caspase-3 and ↓ BCL-2, particularly when combined with tamoxifen.</li>
<li>Chemosensitization through interference with ACLY-dependent lipid metabolic reprogramming; experimentally demonstrated for tamoxifen-sensitive and tamoxifen-resistant breast-cancer cells.</li>
<li>Reduced glycolytic support and tumor-cell migration in ACLY-dependent metabolic contexts; this is secondary and model-dependent rather than a universal HCA effect.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> HCA is orally absorbed, but exposure depends strongly on formulation and food intake. Calcium-only salts have relatively poor solubility, whereas calcium/potassium salts are more water soluble. In a human Phase I crossover study, food reduced HCA peak plasma exposure approximately threefold and total exposure approximately twofold, with substantial inter-individual variability. Earlier human measurements after a 2-g oral dose found plasma concentrations of approximately 0.8–8.4 µg/mL. Consequently, formulation, dose timing, and fed versus fasting state materially affect systemic exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic cancer experiments use HCA concentrations substantially above plasma concentrations produced by ordinary supplement doses. Oral HCA can reach systemic circulation, but millimolar concentrations used in some cell-culture studies are generally difficult to reproduce with conventional nutritional dosing. Exceptionally high oral exposures have reportedly produced substantially higher plasma concentrations, but these should not be treated as equivalent to routine supplement use. Translation of direct in-vitro anticancer effects to standard oral dosing is therefore uncertain.</p>
<p><b>Clinical evidence status:</b> Cancer: primarily preclinical, including cell culture and xenograft/animal studies; limited exploratory human combination experience exists, but there is no established randomized evidence demonstrating HCA as an anticancer treatment. Metabolic/weight management: multiple human randomized trials and systematic reviews exist, but overall weight-loss benefit is small and inconsistent. HCA is marketed as a natural health/dietary supplement rather than an approved cancer drug. Health Canada recognizes calcium/potassium hydroxycitrate as a natural health product ingredient for temporary enhancement of satiety, not for cancer treatment.</p>
<p><b>Safety / translation:</b> Short-term controlled studies generally report tolerability, but gastrointestinal adverse effects occur and post-marketing literature contains cases of clinically significant liver injury associated with <i>Garcinia</i>/HCA-containing products, including rare severe hepatic failure. Attribution can be difficult because many reports involve botanical extracts or multi-ingredient products; however, recent reviews consider a causal relationship plausible in at least a subset of cases. HCA should therefore not be characterized as uniformly non-toxic, particularly with prolonged or high-dose supplementation.</p>
<h3>Hydroxycitric Acid Cancer-Relevant Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ATP citrate lyase</td>
<td>ACLY activity ↓</td>
<td>ACLY activity ↓</td>
<td>Cytosolic acetyl-CoA ↓</td>
<td>Best-established direct biochemical action of HCA. Competitive ACLY inhibition restricts citrate-derived acetyl-CoA required for lipid and cholesterol synthesis; the mechanism itself is not tumor-selective.</td>
</tr>
<tr>
<td>2</td>
<td>De novo lipogenesis</td>
<td>Fatty-acid synthesis ↓; lipid metabolic support ↓</td>
<td>Lipogenesis ↓ (context-dependent)</td>
<td>Membrane and lipid precursor availability ↓</td>
<td>Downstream consequence of ACLY inhibition. Potentially important in tumors dependent on high rates of endogenous lipid synthesis.</td>
</tr>
<tr>
<td>3</td>
<td>AMPK metabolic stress signaling</td>
<td>AMPK ↑ (model-dependent)</td>
<td>AMPK ↑ (context-dependent)</td>
<td>Energy-stress response ↑</td>
<td>Strongly demonstrated in K562 CML cells. AMPK activation should not automatically be generalized to every cancer type or exposure condition.</td>
</tr>
<tr>
<td>4</td>
<td>ER stress and unfolded protein response</td>
<td>eIF2α ↑; ATF4 ↑</td>
<td>Limited evidence</td>
<td>Proteostatic stress ↑</td>
<td>Observed in CML cells and linked mechanistically to HCA-induced metabolic stress, cell-cycle disruption, and DNA fragmentation.</td>
</tr>
<tr>
<td>5</td>
<td>Cell cycle</td>
<td>G2/M arrest ↑; proliferation ↓</td>
<td>Limited evidence</td>
<td>Tumor growth restraint</td>
<td>Demonstrated particularly in CML models downstream of metabolic and ER stress rather than through a conventional cytotoxic drug target.</td>
</tr>
<tr>
<td>6</td>
<td>Apoptotic signaling</td>
<td>Apoptosis ↑; BAX ↑; caspase-3 ↑; BCL-2 ↓</td>
<td>Variable</td>
<td>Programmed cell death ↑</td>
<td>Most evident in selected cancer systems and combination studies. The apoptotic response appears substantially more context-dependent than ACLY inhibition itself.</td>
</tr>
<tr>
<td>7</td>
<td>Tamoxifen chemosensitization</td>
<td>Tamoxifen sensitivity ↑</td>
<td>Not established</td>
<td>Drug response ↑</td>
<td>ACLY inhibition by HCA enhanced tamoxifen cytotoxicity and partially reversed tamoxifen resistance in breast-cancer models. This remains preclinical.</td>
</tr>
<tr>
<td>8</td>
<td>mTOR signaling</td>
<td>mTOR ↑ in CML (model-dependent)</td>
<td>Variable</td>
<td>Adaptive metabolic signaling</td>
<td>CML experiments reported simultaneous AMPK and mTOR activation. This atypical combination argues against simplistically classifying HCA as an mTOR inhibitor.</td>
</tr>
<tr>
<td>9</td>
<td>Glycolytic metabolic support</td>
<td>Glycolytic function ↓ (context-dependent)</td>
<td>Potential ↓</td>
<td>Metabolic flexibility ↓</td>
<td>ACLY inhibition can impair glycolytic tumor phenotypes, but HCA should not be classified as a direct glycolysis inhibitor comparable with agents targeting hexokinase or glucose transport.</td>
</tr>
<tr>
<td>10</td>
<td>Tumor migration</td>
<td>Migration ↓ (model-dependent)</td>
<td>Not established</td>
<td>Invasive phenotype ↓</td>
<td>Reported in glycolysis-dependent glioblastoma models following ACLY inhibition; evidence is much narrower than for the core metabolic mechanism.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Effective experimental exposure may exceed routine systemic exposure</td>
<td>Systemic ACLY and lipid effects remain possible</td>
<td>Clinical anticancer translation uncertain</td>
<td>Food ↓ HCA exposure; formulation strongly affects absorption; substantial PK variability occurs. Human cancer efficacy has not been established, and hepatotoxicity associated with Garcinia/HCA products is an important safety constraint.</td>
</tr>
</tbody>
</table>